Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes

What Was Tested

This randomized controlled trial looks at Insulin Aspart and Insulin Lispro.

To observe whether there are sexual-related differences in response to mid- or low-premixed insulin in type 2 diabetic patients.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The primary endpoint was the differences in glycemic control between male and female patients receiving mid- or low-premixed insulin therapy.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

This was an analysis of CGM data of a previous study.

A 4-day continuous glucose monitoring (CGM) was performed during the cross-over period.

What Was Measured

Topics PubMed links to this paper include Biphasic Insulins, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Hypoglycemia, Hypoglycemic Agents and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart and Insulin Lispro in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of diabetes research), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.